title: Are multicentric Castleman's disease with cutaneous plasmacytosis and systemic plasmacytosis the same entity?
authors.forename: K
authors.initials: K
authors.lastname: Kayasut
authors.forename: A
authors.initials: A
authors.lastname: Le Tourneau
authors.forename: B
authors.initials: B
authors.lastname: Rio
authors.forename: F
authors.initials: F
authors.lastname: Bost-Bezeaud
authors.forename: L
authors.initials: L
authors.lastname: Heuberger
authors.forename: J
authors.initials: J
authors.lastname: Diebold
authors.forename: J
authors.initials: J
authors.lastname: Audouin
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D005871:Castleman Disease / Q000188:drug therapy / Q000473:pathology*; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D010950:Plasma Cells / Q000473:pathology*; D010954:Plasmacytoma / Q000188:drug therapy / Q000473:pathology*; D011239:Prednisolone / Q000627:therapeutic use; D012867:Skin / Q000473:pathology*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011239:Prednisolone